Bliss GVS hits 20% upper circuit as Anupam Rasayan to acquire up to 43% stake for Rs 1,369 crore

About this update from Bliss Gvs Pharma Limited

Bliss GVS Pharma shares hit the 20 percent upper circuit on Tuesday after specialty chemicals firm Anupam Rasayan India announced plans to acquire up to 43.3 percent stake in the company for Rs 1,369.51 crore.The stock of Bliss GVS Pharma was trading at Rs 381.05, up 20 percent, during the session.According to an exchange filing by Anupam Rasayan India, the company will acquire a 43.3 percent stake in Bliss GVS at Rs 299 per share. It will also launch a mandatory open offer to purchase an additional 26 percent stake from public shareholders at the same price.Anupam Rasayan India Managing Director Anand Desai said the company has entered into a definitive agreement for the transaction.The acquisition will be funded through a Rs 300 crore term loan, while the remaining amount will be raised through a non-controlling, non-voting equity instrument, he said.Desai said the deal will help strengthen the company’s presence across the pharmaceutical value chain, from key starting materials to finished dosage formulations.Bliss GVS Pharma, listed on the NSE and BSE, is engaged in the development and export of formulations including suppositories, tablets, capsules and injectables.Incorporated in 1984, the company holds EU-GMP certification and operates manufacturing facilities in Maharashtra and Daman, with approvals from the USFDA and the World Health Organization.It has a portfolio of over 150 branded formulations and is among the country’s large manufacturers of suppositories and pessaries, with presence across Africa, Asia and Latin America.Anupam Rasayan said the combined platform will create an integrated pharmaceutical manufacturing chain with deeper backward integration and wider reach in regulated markets, including Europe and the United States, supported by its earlier acquisition of Jayhawk.Anupam Rasayan India Ltd reported a 40 percent rise in consolidated net profit at Rs 222.19 crore for 2025-26, compared with Rs 159.9 crore in the previous year.(With inputs from PTI)Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

View stock analysis, news, and events for Bliss Gvs Pharma Limited